Navigation Links
Ambiguous Efficacy Of Opioid Drugs In Chronic Inflammatory Joint Pain Relief

Endomorphins are highly powerful a tool for pain management, just as morphine, a problematic narcotic derived from the opium poppy. It has previously been found that endomorphins are able to sidestep concerns// of side effects by virtue of their hard-wired relationship to the body's own pain control receptors. Such receptors, known as u-opioids, appear to be highly sensitized to endomorphins, selectively drawing the natural analgesic to their target spots throughout the peripheral tissue of joints.

Recently a study, published in the October issue of Arthritis and Rheumatism, was conducted to determine whether peripheral administration of the endogenous - opioid peptide endomorphin 1 could reduce knee joint pain, using animal models of acute and chronic arthritis.

Researchers from the University of Calgary, Alberta, Canada looked at the effect of endomorphin 1 on both acute and chronic arthritis in male lab rats. After inducing inflammation in their right knee joints, the researchers treated the rats with endomorphin 1 at various points following the onset of knee arthritis -- either 48 hours post-inflammation during the acute stage of joint pain, or at the one-week or three-week point during the chronic stage.

At all stages of treatment, the electrical activity, or firings, of knee nerve-endings in response to an exaggerated rotation of the joint were measured. Nerve-ending readings were also taken among rats that did not have arthritic knees but were nonetheless also treated with endomorphin.

The researchers found that endomorphin treatment caused nerve activity -- and presumably any related pain -- to drop off by approximately 75% in both normal rats and those with acute arthritis of the knee. However, when injected one or three weeks after the onset of arthritis, endomorphin had no effect on nerve activity. Subsequent autopsies further revealed that beginning one week after induced knee joint inflamm ation, the numbers and activity levels of some local u-opioid receptors had dropped below normal. At three weeks, all receptor activity levels dropped off significantly.

Immunohistochemical and real-time PCR analysis of the L3-L5 dorsal root ganglia ipsilateral to the chronic arthritis lesion revealed a reduction in -opioid receptor protein and gene expression compared with that in normal control animals.

The study concludes on the note that endomorphin, the morphine-like pain control agent, does not have any observable effect on reducing the sensitivity of arthritic joint nerves in the long run. The analgesic effect of endomorphin 1 is lost during chronic inflammation due to down-regulation of -opioid receptor expression in afferent nerve cell bodies. The therapy did, however, provoke a dramatic reduction in short-term joint hypersensitivity. These findings begin to explain the ambiguous efficacy of peripherally administered -opioid drugs in controlling chronic inflammatory joint pain.
'"/>




Related medicine news :

1. Efficacy Of Meningitis C Vaccine
2. The Efficacy Of Allergy Shots Questioned
3. The Efficacy Of Newer Stents Questioned
4. The Efficacy Of Hormone Replacement Therapy Studied
5. Efficacy of fish oil supplements in pregnancy.
6. Efficacy of Omega 3 Fatty Acids Needs Wider Perspective
7. Thailand To Test Efficacy Of Stem Cell Technology
8. Efficacy Of Sports-Formulated Jelly Beans In Warding Off Fatigue To Be Studied
9. Indian And Chinese Doctors Join Together To Prove The Efficacy Of Herbal Drugs
10. New Study Shows Efficacy of AROMASIN on Early Breast Cancer
11. KADIAN Efficacy Not Affected by Alcohol Consumption
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... ... February 17, 2017 , ... Like most hospitals across ... Driven in large part by the Hospital Readmission Reduction Program (HRRP), the return of ... focus area for hospitals across the nation. While many providers are struggling to leverage ...
(Date:2/17/2017)... ... 17, 2017 , ... The Mason Pasquin Agency, a Virginia-based ... owners in and around the Hampton Roads metropolitan region, is joining the local ... domestic violence. , There are multiple categories of domestic violence – physical abuse ...
(Date:2/16/2017)... ... February 17, 2017 , ... Harsha ... 10 years of research, development and clinical trials, the founder of Chigurupati Technologies ... patented compound of FDA approved ingredients that when infused into alcohol, protect the ...
(Date:2/16/2017)... ... 17, 2017 , ... Teaching nursing care of vulnerable children is the focus ... is being created with the support of the Hearst Foundations. An initiative of the ... address what has been identified as a critical gap in preparing the next generation ...
(Date:2/16/2017)... Mt. Kisco, New York (PRWEB) , ... February ... ... Westchester Hospital’s (NWH) nursing professionalism, teamwork and superiority in patient care, NWH ... Chair of the Commission on Magnet on Tuesday, January 31, 2017. The American ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , February 17, 2017 ... the S&P 500 edged lower at the closing bell, ... streak above the 20,000 benchmark. Moreover, five out of ... Taking into consideration yesterday,s market sentiment, Stock-Callers.com assessed the ... & Nephew PLC (NYSE: SNN ), ABIOMED ...
(Date:2/16/2017)... Research and Markets has announced the ... Technologies" report to their offering. ... Traditional medical devices include ... non-drug coated implantables, large endoscopes, needle based drug delivery, lab ... last two to three decades for the treatment and management ...
(Date:2/16/2017)... -- The global preparative and process chromatography market is ... USD 5.49 billion in 2016, at a CAGR of ... the preparative and process chromatography market is segmented into ... chromatography segment is expected to account for the largest ... in this segment can primarily be attributed to the ...
Breaking Medicine Technology: